CVB homepage

APQ Health Cedars Sinai developed the AutoPlaque CCTA coronary plaque analysis software, seen here when it was displayed at the SCCT 2026 meeting. Photo by Dave Fornell.

CCTA results pointed to the regression of total plaque volume in 90% of patients who received more aggressive lipid-lowering therapy and 76% of patients who received intensive lipid-lowering therapy. 

pharmaceutical drug approval process

An Oklahoma pharmaceutical company is accused of failing to comply with federal regulations. The FDA is prepared to remove its statin from the market altogether.

Manesh Patel, MD, FAHA, president of the American Heart Association, chief of the Division of Cardiology, and vice president of heart and vascular services at Duke Health, discusses some trends he saw at the AHA 2026 scientific sessions.

American Heart Association Scientific Sessions 2026 was jam-packed with informative sessions and late-breaking research. AHA President Manesh Patel, MD, discussed some key trends with Cardiovascular Business during the conference.

Coronary artery calcium scans are a simple, noninvasive way to evaluate the calcium deposits in a patient’s coronary arteries. However, the American Heart Association says these tests are not necessarily recommended as a screening modality for all adults. The group believes they work best a 'tiebreaker' when assessing patients who face a borderline or intermediate risk of experiencing a cardiac event.

JenaValve's Trilogy Transcatheter Heart Valve, the only TAVR device approved by the FDA for treating aortic regurgitation, may offer hope for high-risk LVAD patients in need of aortic valve replacement. Additional follow-up data are still necessary, researchers emphasized. 

FDA Recall

The recall was initiated due to a risk of metal contamination that could potentially injure a patient. At this time, however, no adverse events have been reported.

Innovation at work

Nearly half of all American adults over the age of 20 have hypertension, and they face an increased risk of cardiovascular disease, renal events and cerebrovascular events. The recent rise of renal denervation has given cardiologists a new way to fight back against this trend.

Sponsored by Recor Medical

Curtiss Stinis, MD, has been performing TAVR for nearly two decades. He says the new policies from CMS that expand coverage for asymptomatic patients represent a "momentous step forward" for heart patients with severe aortic stenosis.